• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    5/24/24 12:31:03 PM ET
    $APM
    $GNLX
    $HOOK
    $IMTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APM alert in real time by email

    Gainers

    • Innovative Eyewear (NASDAQ:LUCY) shares increased by 328.8% to $0.8 during Friday's regular session. The market value of their outstanding shares is at $13.9 million.
    • OneMedNet (NASDAQ:ONMD) shares increased by 66.66% to $2.45. The market value of their outstanding shares is at $58.4 million.
    • TransCode Therapeutics (NASDAQ:RNAZ) stock rose 28.05% to $1.78. The company's market cap stands at $11.7 million.
    • Onconetix (NASDAQ:ONCO) shares moved upwards by 20.15% to $0.17. The market value of their outstanding shares is at $3.7 million. The company's, Q1 earnings came out 4 days ago.
    • Aptorum Gr (NASDAQ:APM) shares moved upwards by 17.2% to $4.7. The market value of their outstanding shares is at $25.7 million.
    • Immatics (NASDAQ:IMTX) shares moved upwards by 15.98% to $11.39. The company's market cap stands at $1.1 billion.

    Losers

    • Verastem (NASDAQ:VSTM) shares decreased by 63.1% to $4.49 during Friday's regular session. The company's market cap stands at $113.7 million.
    • Sensei Biotherapeutics (NASDAQ:SNSE) stock decreased by 48.96% to $0.74. The market value of their outstanding shares is at $18.5 million.
    • Genelux (NASDAQ:GNLX) stock decreased by 42.0% to $2.67. The company's market cap stands at $72.0 million.
    • Exicure (NASDAQ:XCUR) stock declined by 27.95% to $0.32. The company's market cap stands at $2.7 million.
    • TriSalus Life Sciences (NASDAQ:TLSI) stock declined by 24.53% to $7.2. The market value of their outstanding shares is at $195.5 million.
    • HOOKIPA Pharma (NASDAQ:HOOK) stock fell 22.78% to $0.8. The company's market cap stands at $79.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APM
    $GNLX
    $HOOK
    $IMTX

    CompanyDatePrice TargetRatingAnalyst
    Verastem Inc.
    $VSTM
    2/4/2026$18.00Buy
    H.C. Wainwright
    Genelux Corporation
    $GNLX
    10/21/2025$16.00Buy
    Lake Street
    Verastem Inc.
    $VSTM
    10/16/2025Overweight
    Cantor Fitzgerald
    Immatics N.V.
    $IMTX
    9/18/2025$16.00Buy
    Guggenheim
    Sensei Biotherapeutics Inc.
    $SNSE
    6/2/2025$5.00Buy
    H.C. Wainwright
    Immatics N.V.
    $IMTX
    5/28/2025$10.00Buy
    Deutsche Bank
    Verastem Inc.
    $VSTM
    4/10/2025$15.00Buy
    Jefferies
    Verastem Inc.
    $VSTM
    3/24/2025$7.00 → $10.00Buy
    H.C. Wainwright
    More analyst ratings

    $APM
    $GNLX
    $HOOK
    $IMTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gordon Gary B. bought $40,000 worth of shares (9,756 units at $4.10) (SEC Form 4)

    4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    2/23/26 4:08:23 PM ET
    $TLSI
    Medical Specialities
    Health Care

    Chief Financial Officer Patience David bought $14,994 worth of shares (3,657 units at $4.10), increasing direct ownership by 1% to 268,657 units (SEC Form 4)

    4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    2/23/26 4:08:30 PM ET
    $TLSI
    Medical Specialities
    Health Care

    CEO and President Szela Mary T bought $124,997 worth of shares (30,487 units at $4.10), increasing direct ownership by 4% to 773,289 units (SEC Form 4)

    4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    2/23/26 4:08:06 PM ET
    $TLSI
    Medical Specialities
    Health Care

    $APM
    $GNLX
    $HOOK
    $IMTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Innovative Eyewear, Inc. Announces Q4 and Full Year 2025 Earnings Conference Call

    MIAMI, March 10, 2026 /PRNewswire/ -- Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") (NASDAQ: LUCY; LUCYW), the developer & manufacturer of smart eyewear under the Lucyd®, Lucyd Armor®, Reebok®, Nautica®, and Eddie Bauer® brands, today announced its upcoming earnings conference call to share the Company's key operational and financial results for the fiscal year ended December 31, 2025. Earnings Call DetailsDate: Tuesday, March 31, 2026Time: 12:00 PM ETParticipant Listening OptionsInterested participants can join the event by using the dial-in numbers, or by cl

    3/10/26 4:30:00 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania

    NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, March 10, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences Corp. ("DiamiR"), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced the publication of a paper by Giliberto, et. al. titled "Development of microRNA-Based Glioblastoma Biomarkers Using Blood Plasma Specimens" in Diagnostics, (https://doi.org/10.3390/diagnostics16050791), a leading peer-reviewed journal focused on clinical diagnostics and biomarker research. This study, condu

    3/10/26 8:00:00 AM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

    Hong Kong, March 06, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM), a leading Biotechnology company, today announced that it has received a notification from the Nasdaq Stock Market LLC dated March 5, 2026 regarding non-compliance with the minimum bid price requirement of $1 per share, as per Nasdaq Listing Rule 5550(a)(2). The notification does not immediately affect the listing or trading of the company's shares on Nasdaq. Aptorum Group Limited has been granted a 180-calendar-day grace period, until September 1, 2026, to regain compliance with the noted listing requirement. During this period, Aptorum Group Limited intends to evaluate all available options to restore comp

    3/6/26 4:30:00 PM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APM
    $GNLX
    $HOOK
    $IMTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thomas John sold $28,957 worth of shares (10,000 units at $2.90), decreasing direct ownership by 2% to 482,784 units (SEC Form 4)

    4 - GENELUX Corp (0001231457) (Issuer)

    3/3/26 8:05:01 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Gordon Gary B. bought $40,000 worth of shares (9,756 units at $4.10) (SEC Form 4)

    4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    2/23/26 4:08:23 PM ET
    $TLSI
    Medical Specialities
    Health Care

    Chief Financial Officer Patience David bought $14,994 worth of shares (3,657 units at $4.10), increasing direct ownership by 1% to 268,657 units (SEC Form 4)

    4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    2/23/26 4:08:30 PM ET
    $TLSI
    Medical Specialities
    Health Care

    $APM
    $GNLX
    $HOOK
    $IMTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Verastem with a new price target

    H.C. Wainwright initiated coverage of Verastem with a rating of Buy and set a new price target of $18.00

    2/4/26 8:31:21 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lake Street initiated coverage on Genelux with a new price target

    Lake Street initiated coverage of Genelux with a rating of Buy and set a new price target of $16.00

    10/21/25 7:59:44 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald resumed coverage on Verastem

    Cantor Fitzgerald resumed coverage of Verastem with a rating of Overweight

    10/16/25 8:50:56 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APM
    $GNLX
    $HOOK
    $IMTX
    SEC Filings

    View All

    SEC Form S-8 filed by TriSalus Life Sciences Inc.

    S-8 - TriSalus Life Sciences, Inc. (0001826667) (Filer)

    3/10/26 4:35:59 PM ET
    $TLSI
    Medical Specialities
    Health Care

    SEC Form 6-K filed by Aptorum Group Limited

    6-K - Aptorum Group Ltd (0001734005) (Filer)

    3/6/26 4:30:58 PM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by TriSalus Life Sciences Inc.

    10-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)

    3/5/26 4:08:52 PM ET
    $TLSI
    Medical Specialities
    Health Care

    $APM
    $GNLX
    $HOOK
    $IMTX
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at Air Transport Services Group Inc on Jun 7 Indicate?

    Recently, on June 7, 2024, Michael L Berger, a significant figure at Air Transport Services Group Inc, made a notable insider purchase. Berger bought $49,830 worth of shares, acquiring 3,996 units at a price of $12.47 per share. This transaction increased his direct ownership by 4% to 103,705 units as reported in the SEC Form 4 here. Examining other insider actions within the company can sometimes reveal intriguing patterns that might offer insights for investors. Looking back at previous transactions, we see a series of insider activities at Air Transport Services Group Inc: In March 2024, Dominick Jeffrey A. filed an SEC Form 4, indicating a notable transaction date in which actions were

    6/10/24 12:35:45 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APM
    $GNLX
    $HOOK
    $IMTX
    Leadership Updates

    Live Leadership Updates

    View All

    TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors

    TriSalus Life Sciences, Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology-focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today announced changes to its Board of Directors. TriSalus announced that Dr. Arjun "JJ" Desai, a member of the Board since August of 2023, has elected to resign from the Board. The Company and the Board expressed their sincere appreciation for Dr. Desai's service and contributions during his tenure. Concurrently, TriSalus announced that Michael P. Stansky has been appointed to the Company's Board of Directors, effective February 4, 2026

    2/9/26 9:00:00 AM ET
    $TLSI
    Medical Specialities
    Health Care

    Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer

    WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) --  Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten, M.D., as Chief Medical Officer, effective January 2, 2026. Dr. Litten will oversee all clinical development and medical strategy as the company advances Olvi-Vec through multiple upcoming pivotal milestones. "We are excited to welcome Jason, who is widely recognized for his strategic approach to clinical development and commitment to improving patient outcomes," said Thomas Zindrick, President, CEO, and Chairman of the Board. "He brings extensive experience in oncology drug development of innovati

    1/2/26 8:00:00 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

    BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee.  Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation.

    12/22/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APM
    $GNLX
    $HOOK
    $IMTX
    Financials

    Live finance-specific insights

    View All

    Innovative Eyewear, Inc. Announces Q4 and Full Year 2025 Earnings Conference Call

    MIAMI, March 10, 2026 /PRNewswire/ -- Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") (NASDAQ: LUCY; LUCYW), the developer & manufacturer of smart eyewear under the Lucyd®, Lucyd Armor®, Reebok®, Nautica®, and Eddie Bauer® brands, today announced its upcoming earnings conference call to share the Company's key operational and financial results for the fiscal year ended December 31, 2025. Earnings Call DetailsDate: Tuesday, March 31, 2026Time: 12:00 PM ETParticipant Listening OptionsInterested participants can join the event by using the dial-in numbers, or by cl

    3/10/26 4:30:00 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement

    Acquisition of Faeth and concurrent $200 million private investment positions the combined company to advance its pipeline across key clinical milestones in endometrial and breast cancer PIKTOR is an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway in development across solid tumor settings, including endometrial and breast cancer Sensei to host an audio-only conference call and webcast today, February 18, 2026, at 8:30 a.m. ET Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) today announced that it has acquired Faeth Therapeutics Inc. ("Faeth"), a clinical-stage biotechnology company developing multi-node therapies that target tumor metabolism and signaling. The

    2/18/26 8:00:00 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

    Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its fourth quarter and full year 2025 financial results and business updates on Wednesday, March 4, 2026, at 4:30 pm ET. To access the conference call, please dial (888) 596-4144 (U.S.) or (646) 968-2525 (international) and enter the passcode 7321921 at least 10 minutes prior to the event start time. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's websit

    2/18/26 7:30:00 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APM
    $GNLX
    $HOOK
    $IMTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by TriSalus Life Sciences Inc.

    SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)

    12/4/24 4:00:06 PM ET
    $TLSI
    Medical Specialities
    Health Care

    SEC Form SC 13D filed by Exicure Inc.

    SC 13D - EXICURE, INC. (0001698530) (Subject)

    11/29/24 5:51:28 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Verastem Inc.

    SC 13G/A - Verastem, Inc. (0001526119) (Subject)

    11/14/24 6:25:40 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care